Rubinstein MM, Ge JY, Zhou Q, Iasonos A, et al. A Phase II Trial of Olaparib Plus Pembrolizumab in Patients with Recurrent
Copy-Number High/p53-Abnormal Endometrial Cancer. Clin Cancer Res 2026 Mar 25. doi: 10.1158/1078-0432.CCR-25-4467.
PMID: 41880595
|